(Q36393299)

13 August 2017

Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women (English)

1 reference

13 August 2017

Paul E Goss

1

1 reference

13 August 2017

Peyman Hadji

2

1 reference

13 August 2017

Milayna Subar

3

1 reference

13 August 2017

Paula Abreu

4

1 reference

13 August 2017

Torben Thomsen

5

1 reference

13 August 2017

Jose Banke-Bochita

6

1 reference

13 August 2017

1 January 2007

1 reference

13 August 2017

Breast Cancer Research

1 reference

13 August 2017

9

1 reference

13 August 2017

4

1 reference

13 August 2017

R52

1 reference

https://scigraph.springernature.com/pub.10.1186/bcr1757

13 August 2017

0 references

cites work

The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206728

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206728

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206728

Potential anabolic effects of androgens on bone

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206728

Is bone mineral density predictive of fracture risk reduction?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206728

Biochemical markers of bone turnover and fracture prediction

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206728

Androgen effects on bone and muscle

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206728

Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206728

Clinical review 123: Anabolic therapy for osteoporosis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206728

30 September 2017

Sex steroids and bone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206728

Risks versus benefits in the clinical application of aromatase inhibitors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206728

Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri-, and postmenopausal women

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206728

Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206728

Aromatase in human bone tissue.

30 September 2017

1 reference

Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor letrozole on bone and lipid metabolism in ovariectomized rats.

21 January 2018

1 reference

Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer

21 January 2018

1 reference

Bone loss with exemestane: Is the jury still out?

21 January 2018

1 reference

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy

21 January 2018

1 reference

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

21 January 2018

1 reference

A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer

21 January 2018

1 reference

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

21 January 2018

1 reference

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

21 January 2018

1 reference

The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats.

21 January 2018

1 reference

Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study.

21 January 2018

1 reference

Assessment of four biochemical markers of bone metabolism in postmenopausal osteoporosis.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206728

Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206728

Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206728

Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2206728

Effects of third-generation aromatase inhibitors on bone

21 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17692126

12 December 2020

inferred from PubMed ID database lookup

The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17692126

12 December 2020

inferred from PubMed ID database lookup

Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17692126

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1186/BCR1757

1 reference

Dimensions Publication ID

13 August 2017

1005826893

0 references

Fatcat ID

release_rbxbksi5vjfylgel74t4ib3ns4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rbxbksi5vjfylgel74t4ib3ns4

24 November 2022

mapped directly with Wikidata item

1 reference

13 August 2017

1 reference